asenapine
Nervous system (N05)US regulatory status: approved. Mechanism: Serotonin 2a (5-HT2a) receptor antagonist.
- Mechanism
- Serotonin 2a (5-HT2a) receptor antagonist
pharma · Atopic Dermatitis
Organon Pharma Pty
Organon Pharma Pty Ltd
Organon Pharma Pty drug portfolio — 6 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
SG HQ
2021 Founded
41 Employees
TGA registrant Type
Company details
- Status
- Public
- HQ
- SG
- Founded
- 2021
- Employees
- 41
- Programs
- 1
- Drugs
- 6
- Patents
- 0
Organon Pharma Pty pipeline
Portfolio lens on 6 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Organon Pharma Pty drug portfolio — 6 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
Development asset linked to Organon Pharma Pty in public FDA and regional records.
-
corifollitropin alfa
Genito-urinary system and sex hormones (G03)Genito-urinary system and sex hormones (G03) compound in Organon Pharma Pty's portfolio. Molecular target: Follicle-stimulating hormone receptor.
- Target
- Follicle-stimulating hormone receptor
- Mechanism
- Follicle stimulating hormone receptor agonist
-
US regulatory status: approved. Molecular target: Progesterone receptor.
- Target
- Progesterone receptor
- Mechanism
- Progesterone receptor agonist
-
Development asset linked to Organon Pharma Pty in public FDA and regional records.
-
follitropin beta
Genito-urinary system and sex hormones (G03)Genito-urinary system and sex hormones (G03) compound in Organon Pharma Pty's portfolio. Molecular target: Follicle-stimulating hormone receptor.
- Target
- Follicle-stimulating hormone receptor
- Mechanism
- Follicle stimulating hormone receptor agonist